symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
DAWN,10.485,-1.863518,733281,911920293,0,10.46-25.77,-0.165,"Day One Biopharmaceuticals, Inc.",USD,0001845337,US23954D1090,23954D109,NASDAQ Global Select,NASDAQ,Biotechnology,https://dayonebio.com,"Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.","Dr. Jeremy  Bender M.B.A., Ph.D.",Healthcare,US,124,650 484 0899,395 Oyster Point Boulevard,South San Francisco,CA,94080,,0,https://financialmodelingprep.com/image-stock/DAWN.png,2021-05-27,False,False,True,False,False
